MarketBeat168d agoneutral
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC ConferenceNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
114last 24h
3131last 7d
511● bullish (7d)
314● bearish (7d)
227publishers
Simply Wall St.169d agoneutral
Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price GainsStocktwits170d agobullish
GILD Stock Jumps After Winning Accelerated FDA Approval For HDV TreatmentInsider Monkey171d agobullish
Gilead Sciences (GILD) Is Among The Best Extremely Profitable Stocks To Buy According To Wall Street Analysts24/7 Wall St.171d agobullish
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right NowInsider Monkey172d agoneutral
Morgan Stanley Reassesses Gilead Sciences (GILD) Outlook Following Quarterly ReportInvestorsHub174d agobullish
Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN)MarketBeat175d agoneutral
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation PipelineSimply Wall St.176d agobullish
Evaluating Gilead Sciences (GILD) Valuation After Q1 Beat Guidance Shift And New HIV Priority ReviewSimply Wall St.176d agoneutral
Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board Changes - Has The Bull Case Changed?MarketBeat178d agoneutral
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA ConferenceBarrons.com179d agobullish
Tomato Prices Aren’t the Only Problem. How Retirees Can Beat Inflation.Zacks179d agoneutral
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?StockStory181d agoneutral
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 OutlookInsider Monkey181d agoneutral
Gilead Sciences, Inc. (GILD) Outlook Cut Sharply on $11.5B IPR&D and Financing CostsSimply Wall St.183d agoneutral
Stronger HIV Pipeline And Acquisition Charges Might Change The Case For Investing In Gilead Sciences (GILD)MT Newswires184d agoneutral
Gilead Sciences' Increased Yeztugo Guidance is 'Good Enough' for the Stock, Morgan Stanley Says